China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering

WuXi AppTec
WuXi AppTec's CRO arm will also allow it greater geographic reach. (WuXi-AppTec)

WuXi AppTec’s CRO arm WuXi Clinical will subsume Pharmapace into its business as the China giant looks to up its trial services in biometrics.

The San Diego-based clinical services company offers a host of clinical and statistical programming, data management, biostatistics, clinical data integration and medical writing with clients in North America, Europe and Asia.

With this buy, financial details of which are not being shared, WuXi Clinical boosts its biometrics capabilities in the U.S. and Europe.


De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

There is a high attrition rate during the development of biotherapeutics impacting the high cost of development. Early identification of the preferred expression host for manufacturing, along with lead candidate screening and material supply can help to reduce both attrition rates and cost.

“By integrating Pharmapace and WuXi Clinical China based biometrics teams, we will be able to provide our global customers with efficient and cost effective biometrics service essentially round the clock,” the company said in a statement.

WuXi added: “China's recent regulatory reforms that embrace overseas trial data provide an unprecedented opportunity for innovators around the world to accelerate and integrate clinical development both regionally and globally through the WuXi Clinical organization.”

RELATED: WuXi AppTec hires cancer drug development vet as new CMO

"We are very pleased to welcome Pharmapace to WuXi AppTec. Larry and his leadership team have built a highly reputable biometrics organization in the U.S.," said Edward Hu, co-CEO of WuXi AppTec.

"This acquisition further enhances WuXi Clinical's drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost effectively provide customers seamless biometrics services globally. Together, we are able to shorten time-to-market of new drugs and to achieve the dream that 'every drug can be made and every disease can be treated'."

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

The supermarket chain received an emergency authorization for its own home collection kit for COVID-19 testing, which includes a telehealth consult.

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.